New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTNEPT, ENZY, ACSTNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:38 EDTENZYEnzymotec initiates clinical study of Vayacog in MCI patients
Subscribe for More Information
January 15, 2015
11:44 EDTENZYEnzymotec management to meet with Jefferies
Subscribe for More Information
January 13, 2015
17:14 EDTNEPTNeptune Technologies and NeuroBioPharm announces arrangement agreement
Neptune Technologies & Bioressources and NeuroBioPharm, a subsidiary of Neptune, announce that they have entered into an arrangement agreement which will result in the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio. The Arrangement Agreement provides, amongst other things, that NeuroBio will amalgamate with a newly formed wholly-owned subsidiary of Neptune and that each shareholder of NeuroBio will receive, as applicable, (i) 0.046296296 share of Neptune for each Class A share of NeuroBio held, (ii) 0.185185185 share of Neptune for each Class B share of NeuroBio held, (iii) 0.092592593 share of Neptune for each Class G share of NeuroBio held, and (iv) 0.208333333 share of Neptune for each Class H share of NeuroBio held. An interim order of the Superior Court of Québec granted today provides for, among other things, the calling and holding of a special meeting of shareholders to consider the Arrangement.
17:12 EDTNEPTNeptune Technologies reports Q3 revenue $4.71M, consensus $5.60M.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use